omniture
logo
Search
上海药明生物技术有限公司 WuXi Biologics
Media Room

Latest News

rss

World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target

SHANGHAI, March 21, 2026 /PRNewswire/ -- On the occasion of World Water Day, WuXi Biologics reaffir...

2026-03-22 09:30 5037
World Water Day: WuXi Biologics Advances Water Stewardship and Achieves Water Target

WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation

SINGAPORE, March 12, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global C...

2026-03-13 11:09 5332
WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation

WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year

SHANGHAI, March 1, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Researc...

2026-03-02 11:21 7164
WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

SHANGHAI, Feb. 3, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Researc...

2026-02-03 11:22 10154

WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

SHANGHAI, Jan. 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Researc...

2026-01-29 10:39 9843
WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline

SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a global leading Contract Researc...

2026-01-26 17:35 16915
WuXi Biologics and HanchorBio Enter Strategic Partnership to Advance Next-Generation Bi- and Multi-Functional Fusion Protein Pipeline

JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

* Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 comme...

2026-01-15 12:00 8767

WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic

WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Rese...

2026-01-13 11:07 13230

WuXi Biologics Obtains GMP Certification from UK MHRA for Commercial Manufacturing of an Ophthalmic Biologic

WUXI, China, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Rese...

2026-01-13 11:07 10503

WuXi Biologics Launches Industry-Leading Digital Twin Platform PatroLab™ Designed to Transform Bioprocessing and Manufacturing

SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Researc...

2026-01-12 21:09 10508

WuXi Biologics Achieves ISO 20400 Certification, Setting Benchmark in Sustainable Procurement

WUXI, China, Jan. 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK) announced it has achieved ISO 20...

2026-01-05 11:57 9038

WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security

SHANGHAI, Dec. 19, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK) announced that it has been named t...

2025-12-19 17:30 6088

WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index

* The only company from pharmaceutical industry selected for inclusion in the Index * Also incl...

2025-10-22 08:30 3846

WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year

SHANGHAI, Oct. 9, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research...

2025-10-10 08:30 2217

WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability

* TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integratio...

2025-09-25 19:42 2775

WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year

SHANGHAI, Sept. 23, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Resear...

2025-09-23 12:00 4257

Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK)

WUXI, China, Sept. 17, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Res...

2025-09-17 12:00 2783

WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry

* End-to-end Green CRDMO solutions to enable global clients for broader positive impact * Span ...

2025-09-09 18:00 3815

WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi

* Committed to net-zero across the value chain by 2050 * Aligned with 1.5°C mitigation pathways,...

2025-08-28 17:00 3517

WuXi Biologics Reports Solid 2025 Interim Results

* Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operation...

2025-08-19 20:35 3342
123456